Greenwich LifeSciences, Inc. (GLSI) Financial Statements (2024 and earlier)

Company Profile

Business Address 3992 BLUEBONNET DR, BUILDING 14
STAFFORD, TX 77477
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10,944,24211,911,21913,468,02615,638,08717,187,89019,743,096
Cash and cash equivalents10,944,24211,911,21913,468,02615,638,08717,187,89019,743,096
Total current assets:10,944,24211,911,21913,468,02615,638,08717,187,89019,743,096
Noncurrent Assets
Intangible assets, net (including goodwill)7,1978,1009,0039,90610,80911,712
Intangible assets, net (excluding goodwill)7,1978,1009,0039,90610,80911,712
Total noncurrent assets:7,1978,1009,0039,90610,80911,712
TOTAL ASSETS:10,951,43911,919,31913,477,02915,647,99317,198,69919,754,808
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:300,463220,845220,845220,845220,845220,845
Accrued liabilities1,08314,73042,060   
Other undisclosed accounts payable and accrued liabilities299,380206,115178,785220,845220,845220,845
Other undisclosed current liabilities1,08314,73042,06017,0348,28920,323
Total current liabilities:301,546235,575262,905237,879229,134241,168
Noncurrent Liabilities
Total liabilities:301,546235,575262,905237,879229,134241,168
Equity
Equity, attributable to parent10,649,89311,683,74413,214,12415,410,11416,969,56519,513,640
Common stock12,84812,84812,84812,84812,77512,952
Additional paid in capital55,863,08655,268,56454,674,04254,079,52053,320,02055,117,845
Accumulated deficit(45,226,041)(43,597,668)(41,472,766)(38,682,254)(36,363,230)(35,617,157)
Total equity:10,649,89311,683,74413,214,12415,410,11416,969,56519,513,640
TOTAL LIABILITIES AND EQUITY:10,951,43911,919,31913,477,02915,647,99317,198,69919,754,808

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Operating expenses(1,747,826)(2,241,082)(2,894,683)(2,383,061)(773,307)(1,989,203)
Operating loss:(1,747,826)(2,241,082)(2,894,683)(2,383,061)(773,307)(1,989,203)
Nonoperating income
(Investment Income, Nonoperating)
119,453116,180104,17164,03727,23419,575
Loss from continuing operations:(1,628,373)(2,124,902)(2,790,512)(2,319,024)(746,073)(1,969,628)
Loss before gain (loss) on sale of properties:(2,319,024)(746,073)(1,969,628)
Net loss available to common stockholders, diluted:(1,628,373)(2,124,902)(2,790,512)(2,319,024)(746,073)(1,969,628)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(1,628,373)(2,124,902)(2,790,512)(2,319,024)(746,073)(1,969,628)
Comprehensive loss, net of tax, attributable to parent:(1,628,373)(2,124,902)(2,790,512)(2,319,024)(746,073)(1,969,628)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: